Inhibitors of Raf kinase and MEK signaling

Update on Cancer Therapeutics

Volumn 2, Issue 3, 2007, Pages 111-118

  Ramnath, Nithya ^a   Adjei, Alex ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

ERK; Inhibitors; MEK; RAF; RAS; Signal; Target; Transduction

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; CGP 69846A; CYTOKINE; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; OLIGODEOXYRIBONUCLEOTIDE; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RAF 265; RAF PROTEIN; SORAFENIB; UNCLASSIFIED DRUG;

APOPTOSIS; BLEEDING; BREAST CANCER; CANCER RESEARCH; CELL CYCLE; CELL PROLIFERATION; CLINICAL TRIAL; COLON CANCER; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CYTOTOXICITY; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; EDEMA; ENZYME INHIBITION; EPISTAXIS; FATIGUE; HAND FOOT SYNDROME; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; MELANOMA; NAUSEA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SYNCOPE; THROMBOCYTOPENIA; THYROID CARCINOMA; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER; VOMITING;

EID: 36549044841     PISSN: 1872115X     EISSN: 1872115X     Source Type: Journal    
DOI: 10.1016/j.uct.2007.10.001     Document Type: Review

References (38)

1. Qureshi S.A., Rim M., Bruder J., Kolch W., Rapp U., Sukhatme V.P., et al. An inhibitory mutant of c-Raf-1 blocks v-Src-induced activation of the Egr-1 promoter. J Biol Chem 266 31 (1991) 20594-20597
2. Mavrothalassitis G., and Ghysdael J. Proteins of the ETS family with transcriptional repressor activity. Oncogene 19 55 (2000) 6524-6532
3. Bonnet F., Vigneron M., Bensaude O., and Dubois M.F. Transcription-independent phosphorylation of the RNA polymerase II C-terminal domain (CTD) involves ERK kinases (MEK1/2). Nucleic Acids Res 27 22 (1999) 4399-4404
4. Hurd T.W., Culbert A.A., Webster K.J., and Tavare J.M. Dual role for mitogen-activated protein kinase (Erk) in insulin-dependent regulation of Fra-1 (fos-related antigen-1) transcription and phosphorylation. Biochem J 368 Pt 2 (2002) 573-580
5. Stefanovsky V.Y., Pelletier G., Hannan R., Gagnon-Kugler T., Rothblum L.I., and Moss T. An immediate response of ribosomal transcription to growth factor stimulation in mammals is mediated by ERK phosphorylation of UBF. Mol Cell 8 5 (2001) 1063-1073
6. Weinstein-Oppenheimer C.R., Blalock W.L., Steelman L.S., Chang F., and McCubrey J.A. The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors. Pharmacol Ther 88 3 (2000) 229-279
7. Cowley S., Paterson H., Kemp P., and Marshall C.J. Activation of MAP kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77 6 (1994) 841-852
8. Wasylyk B., Hagman J., and Gutierrez-Hartmann A. Ets transcription factors: nuclear effectors of the Ras-MAP-kinase signaling pathway. Trends Biochem Sci 23 6 (1998) 213-216
9. Blalock W.L., Pearce M., Chang F., Lee J.T., Pohnert S.C., Eurrows C., et al. Effects of inducible MEK1 activation on the cytokine dependency of lymphoid cells. Leukemia 15 5 (2001) 794-807
10. Brennscheidt U., Riedel D., Kolch W., Bonifer R., Brach M.A., Ahlers A., et al. Raf-1 is a necessary component of the mitogenic response of the human megakaryoblastic leukemia cell line MO7 to human stem cell factor, granulocyte-macrophage colony-stimulating factor, interleukin 3, and interleukin 9. Cell Growth Differ 5 4 (1994) 367-372
11. Joneson T., and Bar-Sagi D. Ras effectors and their role in mitogenesis and oncogenesis. J Mol Med 75 8 (1997) 587-593
12. Kolch W., Heidecker G., Lloyd P., and Rapp U.R. Raf-1 protein kinase is required for growth of induced NIH/3T3 cells. Nature 349 6308 (1991) 426-428
13. Santen R.J., Song R.X., McPherson R., Kumar R., Adam L., Jeng M.H., et al. The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 80 2 (2002) 239-256
14. Downward J. Signal transduction Prelude to an anniversary for the RAS oncogene. Science 314 5798 (2006) 433-434
15. Bos J.L. ras oncogenes in human cancer: a review. Cancer Res 49 17 (1989) 4682-4689
16. Slebos R.J., Kibbelaar R.E., Dalesio O., Kooistra A., Stam J., and Meijer C.J. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323 9 (1990) 561-565
17. Mitsudomi T., Steinberg S.M., Oie H.K., Mulshine J.L., Phelps R., and Viallet J. ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 51 18 (1991) 4999-5002
18. Adjei A.A.C.R., Franklin W.A., Molina J., Hariharan S., Temmer F, Brown G., et al. Phase Ib and pharmacokinetic study of the MEK inhibitor AZD6244 (ARRY-142886) in patients with advanced solid tumors. Eur J Cancer 4 Suppl. 12 (2006) 26 [Abstract]
19. Appels N.M., Beijnen J.H., and Schellens J.H. Development of farnesyl transferase inhibitors: a review. Oncologist 10 8 (2005) 565-578
20. Weir B., Zhao X., and Meyerson M. Somatic alterations in the human cancer genome. Cancer Cell 6 5 (2004) 433-438
21. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., and Clegg S. Mutations of the BRAF gene in human cancer. Nature 417 6892 (2002) 949-954
22. Mercer K.E., and Pritchard C.A. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 1653 1 (2003) 25-40
23. Mullen P., McPhillips F., MacLeod K., Monia B., Smyth J.F., and Langdon S.P. Antisense oligonucleotide targeting of Raf-1: importance of raf-1 mRNA expression levels and raf-1-dependent signaling in determining growth response in ovarian cancer. Clin Cancer Res 10 6 (2004) 2100-2108
24. Wilhelm S., and Chien D.S. BAY 43-9006: preclinical data. Curr Pharm Des 8 25 (2002) 2255-2257
25. Moore M., Hirte H.W., Siu L., Oza A., Hotte S.J., and Petrenciuc O. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 16 10 (2005) 1688-1694
26. Strumberg D., Richly H., Hilger R.A., Schleucher N., Korfee S., and Tewes M. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23 5 (2005) 965-972
27. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., and Siebels M. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 2 (2007) 125-134
28. Adjei A.A., Molina J.R., Mandrekar S.J., Marks R., Reid J.R., and Croghan G. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res 13 9 (2007) 2684-2691
29. Llovet J., Ricci S., Mazzaferro V., Hilgard P., Raoul J., Zeuzem M., and For the SHARP Investigators Study Group. ASCO annual meeting proceedings, Part I. Journal of Clinical Oncology vol. 25 No. 18S (2007) LBA1 (June 20 Supplement)
30. Adjei A.A. Signal transduction pathway targets for anticancer drug discovery. Curr Pharm Des 6 4 (2000) 361-378
31. Sebolt-Leopold J.S., Dudley D.T., Herrera R., Van Becelaere K., Wiland A., and Gowan R.C. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 5 7 (1999) 810-816
32. Lorusso P., Krishnamurthi S., Rinehart J.R., Nabell L., Croghan G., and Varterasian M.A. A phase 1-2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer. Proc Am Soc Clin Oncol 24 (2005) [Abstract 3011]
33. Rinehart J., Adjei A.A., Lorusso P.M., Gadgeel S., Reid J., and Mitchell D.Y. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22 22 (2004) 4456-4462
34. Lorusso P.M., Adjei A.A., Varterasian M., Gadgeel S., Reid J., and Mitchell D.Y. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 23 23 (2005) 5281-5293
35. Pratilas C., Sawai A., Ye Q., Lobo J., She Y., and Sebolt-Leopold J. The MEK inhibitor PD0325901 completely inhibits the growth of melanoma tumors with mutationally activated B-Raf. Proc Am Assoc Cancer Res 46 (2005) [Abstract 5285]
36. Grewal T., Tebar F., Pol A., and Enrich C. Involvement of targeting and scaffolding proteins in the regulation of the EGFR/Ras/MAPK. Pathway Oncogen Curr Signal Transduct Ther 1 2 (2006) 147-167
37. Solit D.B., Garraway L.A., Pratilas C.A., Sawai A., Getz G., and Basso A. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439 7074 (2006) 358-362
38. Poynter J.N., Elder J.T., Fullen D.R., Nair R.P., Soengas M.S., and Johnson T.M. BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 16 4 (2006) 267-273